Dugho, Luzviminda B.

HRN: 13-51-80  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/24/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
01/24/2025
01/30/2025
IV
1.5g
Q8
Abscess At Lumbar Are
Waiting Final Action 

 Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

 Final appropriateness: Yes     

 Overall appropriateness: Yes